Here are updates on two of our buys: Regeneron & Broadridge

Article Excerpt

Long-time readers know that we aim to keep you informed of important news about the stocks we cover. That means highlighting developments and plans that promise to bolster investor gains. Here are two buys that stand out this month: REGENERON PHARMACEUTICALS, $901.19, is a buy. The company (Nasdaq symbol REGN; TSINetwork Rating: Average) (www.regeneron.com; Shares o/s: 107.9 million; Market cap: $98.9 billion; No divds.) reports that in the quarter ended December 31, 2023, its revenue rose 0.6%, to $3.43 billion from $3.41 billion a year earlier. Excluding sales of COVID-19 drug Ronapreve, sales rose 14%. Excluding one-time items, per-share earnings fell 5.6%, to $11.86 from $12.56. The company invested more in marketing and research. Regeneron’s commitment to R&D suggests it will continue to add to its FDA approvals and its portfolio of medicines. Notably, it invests a very high 34% of its revenue on research. Meantime, the company holds a big cash balance of $16.2 billion and has long-term debt of just $2.0 billion. The stock remains an attractive…